Atlas Trials

Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer

Clinical trial NCT06748495 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06748495
Sponsor
Hunan Cancer Hospital
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Start date
2024-02-05
Primary completion
2024-12-30
Enrollment
600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.